News

Based on in silico models, AB001 acts on ACE-2 to inhibit the entry of the virus into the cell and also works on NSP15 to prevent its replication.

The randomised and global phase III study will evaluate the efficacy of Farxiga as a treatment in patients hospitalised with COVID-19 who are at risk of developing serious

Delivered through a captivating video game experience, ENDEAVOR is a digital treatment that has been shown in a rigorously designed and conducted clinical research program to improve attention

The agreement specifies that George Mason University’s National Center for Biodefense and Infectious Diseases will provide their unique expertise and resources as a partner in the development of

Follicular lymphoma, which is said to be the second most common form of non-Hodgkins lymphoma (NHL), is an indolent lymphoma and represents around 22% of NHL cases. Claimed

In this regard, Gilead Sciences and Kite have signed a three-year research collaboration agreement with oNKo-innate on cancer immunotherapies with an objective to support the discovery and development

This study will be conducted in collaboration with Advanced Diagnostics Healthcare (ADH) at River Oaks Hospital and Clinics. The hospital has an entire floor dedicated to treating COVID-19

“With the approval of our Emerphed Injection, Nexus Pharmaceuticals is looking to streamline the standard of care in the operating room,” said Mariam S. Darsot, Chief Executive Officer

Systemic sclerosis (SSc), also called as scleroderma, is a disfiguring, disabling and fatal rare autoimmune disease. Nintedanib is a tyrosine kinase inhibitor designed to target crucial receptors engaged